Dr. Roskrow has a background in hematology and oncology and is a senior executive with international experience in the healthcare and financial sectors. She has extensive experience from both early and later-stage clinical development of novel anti-cancer compounds, including therapeutic cancer vaccines, and she has earned several awards and honors for her research work.

In addition to senior clinical and research positions, Dr. Roskrow has extensive experience as an investment banker, CEO and chairperson in both private and listed companies, including the GSF Research Institute (Munich), Patrys Ltd (Melbourne), Imevax (Munich) and Lazard Healthcare Investment Banker (New York, San Francisco, Sydney).

Dr. Roskrow has been involved in executing public and private biotechnology and pharmaceutical merger and acquisition deals, product in/out-licensing deals and financing rounds. In addition, Dr. Roskrow has an extensive network of relationships with executives and board members of pharmaceutical and biotechnology companies and leading clinical centers. She holds BSc (Hons), MBBS (Hons) and a PhD in Immunology, from the University of London.

Dr. Fjällskog is a Senior Life Science Executive with a long track-record within Clinical Research and Development, mainly Immuno-oncology. She is a Board Member of Biovica International AB, Sweden, and serves as Chief Medical Officer in Faron Pharmaceuticals Ltd, Turku, Finland / Boston, a clinical stage biopharmaceutical company focused on cancer and inflammation. Previous to Faron Pharmaceuticals, Dr. Fjällskog was CMO in Sensei Biotherapeutics.

Dr. Fjällskog holds a PhD in oncology and is an Associate Professor (docent) of Oncology, affiliated to Uppsala University, Sweden. Earlier she worked as a medical oncologist with more than 25 years of clinical experience.

Mr. Forbergskog is the CEO of his privately owned investment company, Saturn Invest AS, in addition to being a board member of several companies. From 1989 he was the CFO, and from 2005-2019 the CEO, of Torghatten ASA. During Forbergskog's tenure as CFO/CEO, Torghatten ASA grew from being a small locally based provider of transport services into being one of the Nordics' largest providers of transport services, with more than 7000 employees and an annual turnover of more than NOK 11 billion.

Prior to joining Torghatten ASA, Mr. Forbergskog was an external auditor.

Dr. Hestdal is a Senior Life Science Executive, and was previously the CEO of Photocure ASA - a commercial-stage company focused on bladder cancer and listed on the Oslo Stock Exchange. Presently Dr. Hestdal is a board member and provides consulting services related to development and commercial expertise to pharma, medtech and biotech companies.

Dr. Hestdal holds a PhD in immunology.

Dr. Rieger has about 15 years' experience in cross-functional scientific and business leadership roles spanning business, research operations, drug discovery and product development in the life sciences. Dr. Rieger presently serves as Managing Partner in PBM Capital, where he evaluates new investments, close deals and provides business and technical support to portfolio companies.

Dr. Rieger obtained his PhD from the University of Virginia in Chemistry, has an MBA from the Darden Business School and earned his B.A. from Rollins College.

Dr. Vågesjö is co-founder and CEO of Ilya Pharma AB, a company developing next generation immunotherapies based on cutting edge medical research in immunophysiology and applied microbiology. She has received numerous awards within Science and Innovation, among these, she was one of the winners of Innovators Under 35 Europe from MIT Technology Review 2019 and was featured on the Global PowerList 2021 by the Medicine Maker.

Dr. Vågesjö holds a PhD in Physiology from Uppsala University and a MBA from Heriot-Watt University, Edinburgh.